J Neurol Sci. 2011 Jun 15;305(1-2):22-7. doi: 10.1016/j.jns.2011.02.033. Epub 2011 Mar 25.18. Toledo MA, Junqueira LF Jr et al, Cardiac autonomic modulation and cognitive status in Alzheimer's disease. Clin Auton Res. 2010 Feb;20(1):11-7. 19. Birkhofer A, Schmidt G, Forstl H. Heart and brain -- the influence of psychiatric disorders and their therapy on the heart rate variability. Fortschr Neurol Psychiatr. 2005 Apr;73(4):192-20520. Algotsson A, Viitanen M, Winblad B, Solders G. Autonomic dysfunction in Alzheimer's disease. Acta Neurol Scand. 1995 Jan;91(1):14-8. 21. Wang SJ, Liao KK et al. Cardiovascular autonomic functions in Alzheimer's disease. Age Ageing. 1994 Sep;23(5):400-422. Vitiello B et al. Autonomic dysfunction in patients with dementia of the Alzheimer type. Biol Psychiatry. 1993 Oct 1;34(7):428-33.23. Aharon-Peretz J, Harel T, Revach M, Ben-Haim SA. Increased sympathetic and decreased parasympathetic cardiac innervation in patients with Alzheimer's disease. Arch Neurol. 1992 Sep;49(9):919-2224. Borson S et al. Impaired sympathetic nervous system response to cognitive effort in early Alzheimer's disease. J Gerontol. 1989 Jan;44(1):M8-12.25. Franceschi M eT AL. Signs of cardiac autonomic dysfunction during sleep in patients with Alzheimer's disease. Gerontology. 1986;32(6):327-34.26. Fitzgerald PJ. Is elevated norepinephrine an etiological factor in some cases of Alzheimers disease? Curr Alzheimer Res 2010 Sep;7(6):506-1627. Meel van den Abeelen AS, Lagro J et al. Baroreflex function is reduced in Alzheimers disease: A candidate biomarker? Neurobiol Aging 2012 Nov 7SO197-4580 (12) 00521.28. Livro Teoria da Acidez na Aterosclerose - Novas Evidencias, 2011, Carlos Monteiro, http://www.infarctcombat.org/TeoriadaAcidez.html 29. Weiler PG, Mungas D, Bernick C. Propranolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatry Neurol 1988 Oct-Dec; 1(4):226-3030. Khachaturian AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident alzheimer disease: the cache county study. Archives of Neurology. 2006;63(5):686692.31. Rosenberg PB, Mielke MM, Tschanz J et al. Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatr Psychiatry 2008 November; 16(11):883-89232. Wagner G, Icks A, Abholz HH et al. Antihypertensive treatment and risk of dementia. A retrospective database study. Int J Clin Pharmacol Ther 2012 Mar; 5)(3):195-20133. Wang J, Ono K, Dickstein DL, Arrieta-Cruz I et al. Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. Neurobiol Aging. 2011 Dec;32(12):2321.e1-12.34. Arrieta-Cruz I, Wang J, Pavlides C, Pasinetti GM. Carvedilol reestablishes long-term potentiation in a mouse model of Alzheimer's disease. J Alzheimers Dis. 2010;21(2):649-5435. Lindholm LH, Carlberg B, Samuelsson O. Should B blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-5336. Bangalore S, Steg PHG, Deedwania P, et al. Beta blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012; 308:1340-134937. POISE study group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE Trial): a randomized controlled trial. Lancet 2008; 371: 1839-4738. Rienstra M, Damman K, Mulder BA, et al. Beta-blockers and outcome in heart failure and atrial fibrillation. A meta-analysis. JACC: Heart Fail 2013; 1:21-2839. Mesquita, QHde, Livro Teoria Miogenica do Infarto Miocardico. http://www.infarctcombat.org/TeoriaMiogenica.html 40. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM, Association of serum digoxin concentration and outcomes in patients with heart failure,